The CellCiphr assay panel detects drug-induced hepatotoxicity and is expected to be used early in the drug discovery process. It uses human HepG2 cells in an assay comprised of validated, multiplexed detection reagents and protocols for testing pre-clinical compounds against well recognized cytotoxicity parameters. Profiling compounds with the panel takes advantage of the imaging, sensitivity and multiplexing capability of high content screening instruments (HCS). The ability to recognize potential hepatotoxicity sooner in the drug development pipeline may reduce the cost of identifying toxicity in expensive animal studies. The panel provides multiplexed HCS analysis of 11 human cytotoxicity parameters over three time points (acute at 30 minutes, early at 24 hours and chronic at 72 hours), generating 10-point dose response curves in duplicate for up to 16 test compounds and four control toxins.
